menu
    • menu
    [{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"Imperial College London","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Self-amplifying RNA vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TriLink BioTechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"TriLink BioTechnologies \/ Imperial College London","highestDevelopmentStatusID":"8","companyTruncated":"TriLink BioTechnologies \/ Imperial College London"},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"Chula Vaccine Research Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"ChulaCov19 mRNA Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TriLink BioTechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"TriLink BioTechnologies \/ Chula Vaccine Research Center","highestDevelopmentStatusID":"6","companyTruncated":"TriLink BioTechnologies \/ Chula Vaccine Research Center"},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"EyeGene","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"EG-COVID mRNA COVID-19 vaccine","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"TriLink BioTechnologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"TriLink BioTechnologies \/ EyeGene","highestDevelopmentStatusID":"5","companyTruncated":"TriLink BioTechnologies \/ EyeGene"},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA Covid-19 Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TriLink BioTechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"TriLink BioTechnologies \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"TriLink BioTechnologies \/ Department of Defense"}]

    Find Clinical Drug Pipeline Developments & Deals by Maravai LifeSciences

    Menu

    Maravai LifeSciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    TriLink BioTechnologies

    U.S.A arrow
    BePharma
    Not Confirmed

    TriLink BioTechnologies

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : mRNA Covid-19 Vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Undisclosed

    Sponsor : Department of Defense

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    TriLink BioTechnologies, Part of Maravai LifeSciences, Announces Cooperative Agreement With Department of Defe...

    Details : The agreement includes funding for TriLink’s planned expansion of its nucleic acid production capabilities in San Diego, California. TriLink has experienced substantial demand for a wide range of nucleic acid products in support of multiple COVID-19 mR...

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    May 24, 2022

    Lead Product(s) : mRNA Covid-19 Vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Undisclosed

    Sponsor : Department of Defense

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    TriLink BioTechnologies

    U.S.A arrow
    BePharma
    Not Confirmed

    TriLink BioTechnologies

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : EG-COVID mRNA COVID-19 vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : IND Enabling

    Sponsor : EyeGene

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    TriLink BioTechnologies® Extends EyeGene Partnership for COVID-19 Vaccine Development in South Korea

    Details : EyeGene expected to utilize TriLink’s CleanCap® technology and modified UTP manufactured by TriLink in the production of its EG-COVID mRNA COVID-19 vaccine for clinical trials.

    Product Name : EG-COVID

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    October 04, 2021

    Lead Product(s) : EG-COVID mRNA COVID-19 vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : IND Enabling

    Sponsor : EyeGene

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    TriLink BioTechnologies

    U.S.A arrow
    BePharma
    Not Confirmed

    TriLink BioTechnologies

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ChulaCov19 mRNA Vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase I

    Sponsor : Chula Vaccine Research Center

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    TriLink BioTechnologies® Extends Global Support of Covid-19 Vaccine Development into APAC Region with the Chu...

    Details : The ChulaCov19 mRNA Covid-19 Vaccine Development Program aims to expand access to an mRNA Covid-19 vaccine in Thailand and other low-to-middle-income countries (LMICs) in Asia.

    Product Name : Chula - Cov19

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    August 02, 2021

    Lead Product(s) : ChulaCov19 mRNA Vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Sponsor : Chula Vaccine Research Center

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    TriLink BioTechnologies

    U.S.A arrow
    BePharma
    Not Confirmed

    TriLink BioTechnologies

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Self-amplifying RNA vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase II

    Sponsor : Imperial College London

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    TriLink BioTechn & Imperial College London collaborate to produce saRNA for COVID-19 vaccine development

    Details : Under this development partnership, TriLink will use its robust RNA manufacturing capabilities to respond to the global need for vaccine support against COVID-19.

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    April 28, 2020

    Lead Product(s) : Self-amplifying RNA vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Sponsor : Imperial College London

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth